Evidence map›Paper›PMID 39641026›Full record

ArticleHeliyon2024

Domain architecture of the

Véronique Megalizzi, Abdalkarim Tanina, Camille Grosse, Manon Mirgaux, Pierre Legrand, Gaëtan Dias Mirandela, Alexandre Wohlkönig, Pablo Bifani, René Wintjens

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Véronique MegalizziUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculty of Pharmacy, Université Libre de Bruxelles, Belgium.
Abdalkarim TaninaUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculty of Pharmacy, Université Libre de Bruxelles, Belgium.
Camille GrosseUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculty of Pharmacy, Université Libre de Bruxelles, Belgium.
Manon MirgauxUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculty of Pharmacy, Université Libre de Bruxelles, Belgium.
Pierre LegrandSOLEIL synchrotron, Gif-sur-Yvette, France.
Gaëtan Dias MirandelaBiology of Membrane Transport Laboratory, Molecular Biology Department, Faculty of Sciences, Université Libre de Bruxelles, Belgium.
Alexandre WohlkönigCenter for Structural Biology, Vlaams Institute voor Biotechnology (VIB), Brussels, Belgium.
Pablo BifaniA∗STAR Infectious Diseases Laboratory, Agency for Science, Technology and Research (A∗STAR), Singapore.
René WintjensUnit of Microbiology, Bioorganic and Macromolecular Chemistry, Department of Research in Drug Development, Faculty of Pharmacy, Université Libre de Bruxelles, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MabR (

Indexed as

AlphaFoldDNA-BindingElectron microscopyFAS-IIGel filtrationMycolic acidsOligomerizationSAXSX-ray crystallography

Identifiers

PMID39641026
PMCPMC11617747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.